Colchicine Versus Placebo After Pulmonary Vein Isolation
common.study.values.description
“Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)”
Recurrence is a common problem after catheter ablation for atrial fibrillation, affecting at least one out of three patients. Inflammation due to the procedure may contribute to pulmonary vein reconnection and, thus, failure of catheter ablation. This pilot study will assess whether a randomized, placebo-controlled, double-blind trial investigating a 10-day treatment with colchicine, a potent anti-inflammatory drug, to improve patient relevant outcomes after catheter ablation for atrial fibrillation is feasible.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Colchicine 0.6 mg
p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
Drug - Matching placebo
p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
participant.views.study.view.additional
participant.views.study.view.scientific-title
Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI): A Pilot Study
common.study.values.clinical-trial-id
NCT04160117
participant.views.study.view.id
eZ676e
